JPMorgan Chase & Co. Decreases Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

JPMorgan Chase & Co. trimmed its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 10.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 365,921 shares of the company's stock after selling 43,320 shares during the quarter. JPMorgan Chase & Co. owned 0.47% of Kura Oncology worth $3,187,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in KURA. Jane Street Group LLC lifted its holdings in shares of Kura Oncology by 36.7% in the third quarter. Jane Street Group LLC now owns 126,085 shares of the company's stock worth $2,464,000 after buying an additional 33,848 shares in the last quarter. Barclays PLC lifted its stake in Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company's stock worth $3,234,000 after purchasing an additional 84,563 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Kura Oncology by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after purchasing an additional 41,535 shares during the period. Franklin Resources Inc. grew its position in shares of Kura Oncology by 1.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after purchasing an additional 23,113 shares in the last quarter. Finally, Harbor Capital Advisors Inc. grew its position in shares of Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock valued at $430,000 after purchasing an additional 2,076 shares in the last quarter.

Analysts Set New Price Targets

KURA has been the subject of several recent analyst reports. Cantor Fitzgerald upgraded Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Tuesday, April 8th. Scotiabank dropped their target price on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. Finally, UBS Group lowered their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $25.50.

Insider Activity at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock valued at $92,307 in the last three months. Company insiders own 6.40% of the company's stock.

Kura Oncology Price Performance

Shares of KURA remained flat at $6.43 during trading hours on Friday. The stock had a trading volume of 984,566 shares, compared to its average volume of 1,147,182. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company's 50-day moving average is $6.88 and its 200 day moving average is $10.05. The firm has a market cap of $519.40 million, a price-to-earnings ratio of -2.72 and a beta of 0.83.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analysts' expectations of $57.96 million. On average, research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.